<DOC>
	<DOC>NCT02578082</DOC>
	<brief_summary>This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal renal function or severe (eGFR &lt;30 mL/min/1.73 m2) renal impairment to evaluate the effect of renal impairment on the pharmacokinetics (PK) of TD 4208.</brief_summary>
	<brief_title>Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>For renal impairment group: Subject has severe renal impairment (eGFR &lt;30 mL/min/1.73 m2) For normal renal function group: Subject is in good health Women who are pregnant, lactating, breastfeeding, or planning to become pregnant during the study. Subject has received an investigational drug (or medical device) within 30 days Subject who, for any reason, is deemed by the investigator to be inappropriate for this study; or has any condition that would confound or interfere with the evaluation of the safety, tolerability, or PK of the investigational drug; or is unable to comply with the study protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Renal Impairment</keyword>
	<keyword>Renal Insufficiency</keyword>
</DOC>